Skip to content
10-Q

Quarterly Report

SELLAS Life Sciences Group, Inc. SLS

0001390478-25-000008

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 99.78M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $28.4M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $13.89M
Current Liabilities Q1 2025 · Mar 31, 2025 $6.89M
Current Liabilities Q1 2025 · Dec 31, 2024 $9.51M
Total Liabilities Q1 2025 · Mar 31, 2025 $7.2M
Total Liabilities Q1 2025 · Dec 31, 2024 $9.97M
Current Assets Q1 2025 · Mar 31, 2025 $31.97M
Current Assets Q1 2025 · Dec 31, 2024 $16.33M
Total Assets Q1 2025 · Mar 31, 2025 $34.96M
Total Assets Q1 2025 · Dec 31, 2024 $19.43M
Sga Expense Q1 2025 · Mar 31, 2025 $2.86M
Sga Expense Q1 2025 · Mar 31, 2024 $4.53M
Shares Diluted Q1 2025 · Mar 31, 2024 44.81M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$10.76M
Stockholders Equity Q1 2025 · Mar 31, 2024 $9.68M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$7.98M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.21
Eps Basic Q1 2025 · Mar 31, 2024 −$0.21
Net Income Q1 2025 · Mar 31, 2024 −$9.57M
Operating Income Q1 2025 · Mar 31, 2024 −$9.65M